BMO Capital Downgrades Pfizer To Market Perform, Shares Drop

BMO Capital downgraded Pfizer

from Outperform to Market Perform. The target price for Pfizer has been lowered from $34 to $31. Pfizer shares have surged 2.20% over the past 52 weeks, while the S&P 500 index has gained 17.39% in the same period. Pfizer's shares dropped 1.29% to $29.95 in pre-market trading.